Last updated: February 16, 2026
Overview of the Product
NDC 76385-0132 corresponds to Nurtec ODT (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute treatment of migraine and preventive therapy. Approved by the FDA in 2020, Nurtec has gained significant market share in the migraine treatment landscape.
Market Landscape
-
Size and Growth: The global migraine drug market was valued at approximately $4.8 billion in 2022. The CGRP inhibitor segment accounts for about 25% of this market. The segment is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030. (Source: IQVIA, MarketsandMarkets)
-
Key Competitors: Other CGRP therapies include Ajovy (fremanezumab), Emgality (galcanezumab), and Aimovig (erenumab). Nurtec's notable advantages are its oral formulation and rapid onset.
-
Market Penetration: As of 2022, Nurtec held roughly 15% of the CGRP segment, with sales surpassing $600 million globally. Sales are expected to increase as awareness and insurance coverage expand.
-
Prescribing Trends: There is increasing preference for oral medications due to convenience, contributing to Nurtec’s growing prescription volume.
Pricing Strategies and Historical Price Trends
-
List Price: The wholesale acquisition cost (WAC) for Nurtec ODT was approximately $722 for a 30-count pack in late 2022. The average wholesale price (AWP) slightly exceeds this, around $755.
-
Reimbursement Context: With insurance, out-of-pocket costs for patients are generally between $30 and $80, depending on insurance plan coverage and discounts.
-
Price Trends (2020–2022): The list price has remained relatively stable, with minor adjustments annually. No significant manufacturer-initiated price reductions or discounts have been publicly reported.
-
Pricing Compared to Competitors:
| Drug |
Formulation |
List Price (Approx.) |
Monthly Cost (Estimate) |
Market Position |
| Nurtec ODT |
Oral |
$722 per 30 tabs |
~$722 per month |
Oral alternative, rapid onset |
| Aimovig |
Injectable |
~$6,000 per year |
~$500 per month (adjusted) |
Self-injectable, long-term use |
| Emgality |
Injectable |
~$6,600 per year |
~$550 per month |
Monthly injectables, preventive use |
Regulatory and Patent Considerations
-
Patent Lifecycle: Patents for Nurtec are valid until at least 2030, barring challenge or extension, providing exclusivity that supports pricing stability.
-
Regulatory Approvals: Approved for both acute and preventive migraine treatment, which broadens market potential.
Price Projection Scenarios (Next 5 Years)
| Scenario |
Assumptions |
Price Trend |
Rationale |
| Conservative |
Stable market, no significant patent expiry before 2027 |
Price remains at ~$722 WAC |
Market dominance persists, minimal pressure for price cuts, stable insurance reimbursement rates |
| Moderate |
Increased competition, some biosimilar entries |
Potential 5% annual decrease in list price |
Entry of biosimilars or generics could pressure pricing, though rapid patent expiry unlikely before 2027 |
| Aggressive |
Patent expiry in late 2024, market saturation |
Price drops by 15–20% upon patent expiration |
Biosimilar competition reduces prices significantly, and market saturation limits price increases |
Impact of Biosimilar and Generics Entry
At present, Nurtec's oral formulation and patent protection mitigate immediate biosimilar threats. However, patent cliffs typically induce substantial price declines. Industry estimates suggest that upon patent expiration, oral CGRP agents could see prices fall by 15–25%.
Potential Market and Price Dynamics
-
Market Expansion: Growing awareness and broader insurance coverage could sustain or increase sales volume, supporting more stable prices.
-
Negotiation Power: Payers may negotiate discounts, particularly as more CGRP options enter the market. Manufacturer list prices are likely to decrease post-patent expiry or with intensified rebate strategies.
-
Regulatory Developments: No recent regulatory changes are expected to significantly alter Nurtec’s market position or pricing.
Summary
Nurtec ODT (NDC 76385-0132) is positioned within a growing migraine treatment segment, characterized by stable list pricing and increasing adoption. Its competitive advantage derives from oral administration and patent exclusivity. Price projections indicate potential stabilization until patent expiry, with possible reductions following biosimilar market entry at the end of the current patent lifecycle (~2024–2025).
Key Takeaways
-
Nurtec ODT maintains a stable list price of approximately $722 for a 30-count pack, with monthly patient costs around $30–$80 due to insurance coverage.
-
Market growth is driven by increased adoption, with the CGRP segment expanding at 8% CAGR through 2030.
-
Patent protections prevent immediate biosimilar entry until at least 2024, supporting pricing stability.
-
Post-patent expiration, prices could decline 15–25%, influenced by biosimilar competition and payer negotiations.
-
Market share is expanding, supported by advantages over injectable competitors, but future pricing faces downward pressure from generic options.
Frequently Asked Questions
1. When might biosimilar versions of Nurtec become available?
Biosimilar entry is unlikely before patent expiry, projected around 2024–2025, unless legal challenges or patent extensions alter this timeline.
2. How does insurance coverage impact patient pricing?
Most insurers cover Nurtec, with out-of-pocket costs typically ranging from $30 to $80, depending on plan deductibles and co-pay assistance programs.
3. Are there upcoming label expansions that could influence market size?
No recent FDA approvals extend Nurtec’s label beyond current indications, but ongoing studies could support future label expansions.
4. How does Nurtec compare price-wise to injectable CGRP therapies?
Nurtec is more affordable on a monthly basis ($722 vs. ~$550 for injectables), with the added convenience of oral administration influencing its market position.
5. What factors could accelerate price reductions for Nurtec?
Patent expiry, entry of biosimilars, increased market competition, and payer negotiations could all contribute to lower prices.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] MarketsandMarkets. (2022). Migraine Drugs Market Forecast.
[3] FDA. (2020). Nurtec ODT Approval Documentation.
[4] Healthcare Pricing Data. (2022). Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC).
